Author

Gray RT

14 ноября 2018 г.
Австралия продвигается к достижению целей ВОЗ по элиминации ВГС после быстрого начального применения ПППД - модельное исследование
Summary Subsidized direct-acting antiviral (DAA) treatment recently became available to all adults living with chronic hepatitis C (HCV) in Australia. Based on rapid uptake (32,600 people initiated DAA in 2016) we estimated the impact on HCV epidemiology and mortality in Australia and determined if Australia can meet the WHO HCV elimination targets by 2030. Using […]

Читать далее
Январь 30, 2017
Бремя хронического гепатита С и каскад лечения в Австралии в эпоху лечения на основе интерферона
Summary Background and aim Interferon-free direct-acting antiviral regimens for hepatitis C virus (HCV) infection have been recently available in Australia, beginning a new era in clinical and public health management of HCV infection. This study provided updated estimates of the HCV infection care cascade and burden in Australia as a reliable platform for assessing the […]

Читать далее